{"id":559039,"date":"2021-08-23T11:04:02","date_gmt":"2021-08-23T11:04:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=559039"},"modified":"2021-08-23T11:04:02","modified_gmt":"2021-08-23T11:04:02","slug":"polymyalgia-rheumatica-market-insights-epidemiology-and-market-forecast2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/polymyalgia-rheumatica-market-insights-epidemiology-and-market-forecast2030_559039.html","title":{"rendered":"Polymyalgia Rheumatica Market Insights, Epidemiology, And Market Forecast-2030"},"content":{"rendered":"
\n
\"Polymyalgia<\/a><\/div>\n
\n
DelveInsight Business Research LLP <\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s \u2018Polymyalgia Rheumatica Market\u2019 report deliver an in-depth understanding of the Polymyalgia Rheumatica (PMR), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n

Polymyalgia Rheumatica Market<\/strong><\/p>\n

The Polymyalgia Rheumatica (PMR) market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted PMR symptoms market size from 2018 to 2030 segmented by seven major markets. The report also covers current Polymyalgia Rheumatica (PMR) symptoms treatment practice\/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.<\/p>\n

Polymyalgia Rheumatica (PMR) Market Outlook<\/strong><\/p>\n

The Polymyalgia Rheumatica (PMR) market outlook <\/a>of the report helps build a detailed comprehension of the historic, current, and forecasted Polymyalgia Rheumatica (PMR) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.<\/p>\n

This segment gives a thorough detail of Polymyalgia Rheumatica (PMR) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.<\/p>\n

According to DelveInsight, Polymyalgia Rheumatica (PMR) market in 7MM is expected to change in the study period 2018–2030.<\/p>\n

Key Findings<\/p>\n

This section includes a glimpse of the Polymyalgia Rheumatica market <\/a>in 7MM. The market size of PMR in the seven major markets was found to be USD 2,893.57 million in 2020, and the market is estimated to increase at a CAGR of 13.60% for the study period (2018–2030).<\/p>\n

The United States Market Outlook<\/p>\n

This section provides a total of Polymyalgia Rheumatica (PMR) market size and market size by therapies in the United States.<\/p>\n

The United States accounts for the highest PMR market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.<\/p>\n

EU-5 Countries: Market Outlook<\/p>\n

The total Polymyalgia Rheumatica (PMR) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.<\/p>\n

Japan Market Outlook<\/p>\n

The total Polymyalgia Rheumatica (PMR) market size and market size by therapies in Japan are also mentioned.<\/p>\n

Table of contents<\/p>\n

1. Key Insights<\/p>\n

2. Report Introduction<\/p>\n

3. Polymyalgia Rheumatica Market Overview at a Glance<\/p>\n

3.1. Market Share (%) Distribution of Polymyalgia Rheumatica in 2018<\/p>\n

3.2. Market Share (%) Distribution of Polymyalgia Rheumatica in 2030<\/p>\n

4. Executive Summary of Polymyalgia Rheumatica<\/p>\n

5. Disease Background and Overview<\/p>\n

5.1. Introduction<\/p>\n

5.2. Symptoms<\/p>\n

5.3. Etiology<\/p>\n

5.4. Pathogenesis<\/p>\n

5.5. Clinical Manifestation<\/p>\n

5.6. Diagnosis<\/p>\n

5.6.1. Classification Criteria<\/p>\n

6. Management and Treatment of PMR<\/p>\n

6.1. EULAR\/ACR Recommendation<\/p>\n

6.2. Treatment Algorithm<\/p>\n

7. Epidemiology and Patient Population<\/p>\n

7.1. Key Findings<\/p>\n

7.2. 7MM Total Prevalent Patient Population of Polymyalgia Rheumatica<\/p>\n

7.3. Epidemiology of Polymyalgia Rheumatica<\/p>\n

7.4. The United States<\/p>\n

7.4.1. Prevalence of Polymyalgia Rheumatica in the United States<\/p>\n

7.4.2. Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in the United States<\/p>\n

7.4.3. Gender-specific Prevalence of Polymyalgia Rheumatic in the United States<\/p>\n

7.4.4. Diagnosed Cases of GCA in PMR in the United States<\/p>\n

7.5. EU5<\/p>\n

7.5.1. Germany<\/p>\n

7.5.2. France<\/p>\n

7.5.3. Italy<\/p>\n

7.5.4. Spain<\/p>\n

7.5.5. United Kingdom<\/p>\n

7.6. Japan<\/p>\n

7.6.1. Prevalence of Polymyalgia Rheumatica in Japan<\/p>\n

7.6.2. Prevalent Cases of Polymyalgia Rheumatica based on clinical manifestation in Japan<\/p>\n

7.6.3. Gender-specific Prevalence of Polymyalgia Rheumatic in Japan<\/p>\n

7.6.4. Diagnosed Cases of GCA in PMR in Japan<\/p>\n

8. Organizations contributing towards Polymyalgia Rheumatica<\/p>\n

9. Patient Journey<\/p>\n

10. Case Reports<\/p>\n

11. Emerging Therapies<\/p>\n

11.1. Tocilizumab: Roche Chugai<\/p>\n

11.1.1. Drug Description<\/p>\n

11.1.2. Other Development Information<\/p>\n

11.1.3. Clinical Development<\/p>\n

11.1.4. Clinical Trials Information<\/p>\n

11.1.5. Safety and Efficacy<\/p>\n

11.1.6. Product Profile<\/p>\n

11.2. Abatacept: Bristol-Myers Squibb<\/p>\n

11.2.1. Drug Description<\/p>\n

11.2.2. Other Development Information<\/p>\n

11.2.3. Clinical Development<\/p>\n

11.2.4. Clinical Trials Information<\/p>\n

11.2.5. Product Profile<\/p>\n

11.3. Baricitinib: Eli Lilly<\/p>\n

11.3.1. Drug Description<\/p>\n

11.3.2. Other Development Information<\/p>\n

11.3.3. Clinical Development<\/p>\n

11.3.4. Clinical Trials Information<\/p>\n

11.3.5. Safety and Efficacy<\/p>\n

11.3.6. Product Profile<\/p>\n

12. Polymyalgia Rheumatica: 7 Major Market Analysis<\/p>\n

12.1. Key Findings<\/p>\n

12.2. Market Size of Polymyalgia Rheumatica in 7MM<\/p>\n

12.3. Market Size of Polymyalgia Rheumatica by Therapies<\/p>\n

13. Market Outlook<\/p>\n

13.1. United States Market Size<\/p>\n

13.1.1. Total Market Size of Polymyalgia Rheumatica in the United States<\/p>\n

13.1.2. Market Size of Polymyalgia Rheumatica by Therapies in the United States<\/p>\n

13.2. EU-5 Market Size<\/p>\n

13.2.1. Germany<\/p>\n

13.2.2. France<\/p>\n

13.2.3. Italy<\/p>\n

13.2.4. Spain<\/p>\n

13.2.5. United Kingdom<\/p>\n

13.3. Japan<\/p>\n

13.3.1. Total Market size of Polymyalgia Rheumatica in Japan<\/p>\n

13.3.2. Market Size of Polymyalgia Rheumatica by Therapies in Japan<\/p>\n

14. KOL Views<\/p>\n

15. Market Access<\/p>\n

16. Market Drivers<\/p>\n

17. Market Barriers<\/p>\n

18. SWOT Analysis<\/p>\n

19. Unmet Needs<\/p>\n

20. Appendix<\/p>\n

20.1. Bibliography<\/p>\n

20.2. Report Methodology<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

23. About DelveInsight<\/p>\n

Request sample report of Polymyalgia Rheumatica Market Trends<\/a><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight<\/a>
Contact Person:<\/strong> Priya Maurya
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 09650213330
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Albany
State:<\/strong> New York
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight\u2019s \u2018Polymyalgia Rheumatica Market\u2019 report deliver an in-depth understanding of the Polymyalgia Rheumatica (PMR), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-559039","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/559039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=559039"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/559039\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=559039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=559039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=559039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}